Phase 2 N=91 Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery
Inflammation
Primary: Anterior Chamber Cell: Categorical Cure — 18; 16; 6 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=25 Treating Inflammation in Polycystic Ovary Syndrome to Ameliorate Ovarian Dysfunction
Polycystic Ovary Syndrome
Primary: Aim 1: HCG-stimulated Testosterone Area Under the Curve — 4458; 7775 Nonograms*Hour per Deciliter (ng*hr/dL) — p=<0.004
Phase 2 N=17 Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations
Advanced Malignant Solid Neoplasm · Cholangiocarcinoma · Metastatic Malignant Solid Neoplasm
Primary: Overall Response Rate (ORR) — 13.3 percentage of participants
Phase 2 N=8 A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease
Alzheimer Disease
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs — 4; 1; 8; 4 Participants
Phase 2 N=6 MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab
Adenocarcinoma of the Colon · Adenocarcinoma of the Rectum
Primary: Progression Free Survival (PFS) — 0; 0 Participants
Phase 2 N=267 A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease
Atherosclerotic Cardiovascular Disease
Primary: Percentage Change in Low-density Lipoprotein (LDL)-Cholesterol — -27; -41; -55; 6 Percentage change of LDL cholesterol — p=<.0001
Phase 2 N=90 Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma
Ann Arbor Stage II Grade 1 Follicular Lymphoma · Ann Arbor Stage II Grade 2 Follicular Lymphoma · Ann Arbor Stage III Grade 1 Follicular Lymphoma
Primary: Progression Free Survival — 70.7 months
Phase 2 N=177 Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001
High Grade Glioma · Astrocytoma, Grade III · Glioblastoma
Primary: Phase 1: Maximum Tolerated Dose (MTD) of BMX-001 Administered in Combination With Standard RT and TMZ in Newly Diagnosed HGG Patients — NA mg/Participant
Phase 2 N=14 Injections of Glutamic Acid Decarboxylase (GAD) for LADA Type of Diabetes
Latent Autoimmune Diabetes in Adults
Primary: Injection Site Skin Reactions — 4 events
Phase 2 N=15 Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)
Metastatic Castration-resistant Prostate Cancer · Prostate Cancer · Prostate Neoplasm
Primary: Clinical Benefit With Any of a Set of 3 Possible Treatments for Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Reported With an 80% Confidence…
Phase 2 N=53 Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment
Breast Neoplasm · Metastasis
Primary: Time to Progression — 4.1 months
Phase 2 N=11 A Study of Deucravacitinib to Treat LPP and FFA
Lichen Planopilaris
Primary: Complete and Partial Response to Deucravacitinib Measured by Lichen Planopilaris Activity Index (LPPAI) Score — 9 Participants
Phase 2 N=45 A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial
Hidradenitis Suppurativa
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 15; 28 Participants
Phase 2 N=25 Study of NKTR 255 in Combination With Cetuximab in Solid Tumors
Head and Neck Squamous Cell Carcinoma · Colorectal Cancer
Primary: Incidence of Treatment-Emergent Adverse Events (TEAE) and Serious Adverse Events (SAE) of NKTR-255 in Combination With Cetuximab in R/R HNSCC or CRC for Phase 1b Dose…
Phase 2 N=100 Mandibular Advancement vs Home Treatment for Primary Snoring
Snoring
Primary: Percent Responders of Clinical Global Impression of Improvement Scale - Partner — 91; 58 percent of snorer responders